PortfoliosLab logo
BIOLASE, Inc. (BIOL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0909112072

CUSIP

090911207

IPO Date

Nov 13, 1992

Highlights

Market Cap

$439.17K

EPS (TTM)

$16.18

PE Ratio

0.00

PEG Ratio

-0.22

Total Revenue (TTM)

$11.56M

Gross Profit (TTM)

$4.61M

EBITDA (TTM)

-$1.43M

Year Range

$0.01 - $0.20

Target Price

$1.20

Short %

5.00%

Short Ratio

1.09

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period


BIOL

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.86%

1M

8.72%

6M

-2.74%

1Y

11.65%

5Y*

15.28%

10Y*

10.67%

*Annualized

Monthly Returns

The table below presents the monthly returns of BIOL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-33.50%-81.50%37.54%-21.87%15.17%-41.45%-30.90%-15.92%122.03%-87.98%-98.62%
2023-16.43%-6.11%-44.86%-11.10%-67.40%-13.25%-13.86%-28.24%-57.44%-9.68%-35.12%2.94%-98.27%
2022-5.26%-4.98%0.60%-47.90%5.00%-5.18%-3.28%-12.64%-37.21%-19.34%-50.71%-32.71%-93.33%
2021171.18%-19.72%-7.09%-11.48%-2.83%-3.71%-18.02%34.11%-16.70%-12.40%-21.36%-11.44%-6.41%
20208.56%7.50%-41.86%15.60%-7.75%15.78%-11.66%-23.99%-11.51%-5.49%15.73%38.48%-24.61%
201983.84%40.66%-7.03%-13.87%-19.51%-10.91%5.44%-38.71%-1.05%-38.40%1.05%-5.54%-44.17%
2018-2.27%-0.41%-2.17%-13.05%-24.07%-9.71%2.48%42.74%16.95%-36.23%-12.88%-13.91%-53.56%
201711.43%-6.41%-7.53%-5.19%-13.28%-12.61%-13.30%-39.45%18.38%17.78%-29.58%-14.72%-69.54%
201611.38%-5.00%47.19%8.40%-18.31%0.86%-3.42%56.64%-1.13%-18.29%22.38%-20.00%66.45%
2015-2.67%-15.23%-6.91%0.50%-16.26%2.35%-15.52%2.04%-40.00%-0.00%0.56%-7.06%-68.02%
2014-14.49%27.69%-21.62%-19.92%-3.11%17.65%0.91%-2.70%15.28%-4.42%7.98%2.33%-6.60%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BIOL is 37, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BIOL is 3737
Overall Rank
The Sharpe Ratio Rank of BIOL is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of BIOL is 6666
Sortino Ratio Rank
The Omega Ratio Rank of BIOL is 7474
Omega Ratio Rank
The Calmar Ratio Rank of BIOL is 11
Calmar Ratio Rank
The Martin Ratio Rank of BIOL is 1010
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for BIOLASE, Inc. (BIOL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for BIOLASE, Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


BIOLASE, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the BIOLASE, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BIOLASE, Inc. was 100.00%, occurring on Sep 27, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Jan 22, 20045207Sep 27, 2024
-97.5%Nov 30, 1992535Apr 28, 19952173Jan 16, 20042708
-5.13%Nov 18, 19921Nov 18, 19923Nov 23, 19924
-2.5%Nov 25, 19921Nov 25, 19921Nov 27, 19922

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of BIOLASE, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of BIOLASE, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -14.3%.


-8.00-6.00-4.00-2.000.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024April
-0.08
-0.07
Actual
Estimate

Valuation

The Valuation section provides an overview of how BIOLASE, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for BIOL, comparing it with other companies in the Medical Devices industry. Currently, BIOL has a P/E ratio of 0.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BIOL compared to other companies in the Medical Devices industry. BIOL currently has a PEG ratio of -0.2. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BIOL relative to other companies in the Medical Devices industry. Currently, BIOL has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BIOL in comparison with other companies in the Medical Devices industry. Currently, BIOL has a P/B value of 0.8. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items